Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad191 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Frank Siebenhaar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Agents, Mastocytosis, Mastocytosis, Systemic. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Allakos, Inc.
Abstract (Originalsprache)
Background
Indolent systemic mastocytosis (ISM) is characterized by excessive mast cell (MC) accumulation and MC-driven signs and symptoms. Currently used therapies are not approved and have limited efficacy. Lirentelimab (AK002) is a monoclonal antibody against sialic acid-binding immunoglobulin-like lectin (Siglec)-8 that inhibits MC activation.
Objectives
To determine the safety, tolerability and efficacy of lirentelimab in reducing the symptoms of ISM.
Methods
At a specialty centre for mastocytosis in Germany, we conducted a phase I first-in-human single-ascending and multidose clinical trial of lirentelimab in patients with ISM. Eligible adults had World Health Organization-confirmed ISM and an unsatisfactory response to available treatment. In part A, patients received a single dose of lirentelimab 0.0003, 0.001, 0.003, 0.01 or 0.03 mg kg–1; in part B, patients received one lirentelimab dose of 0.3 mg kg–1 or 1.0 mg kg–1; and in part C, patients received either 1.0 mg kg–1 lirentelimab every 4 weeks for 6 months or ascending doses of lirentelimab (one dose of 1 mg kg–1 followed by five doses of 3–10 mg kg–1 every 4 weeks). The primary endpoint was safety/tolerability. Secondary endpoints included changes from baseline in Mastocytosis Symptom Questionnaire (MSQ), Mastocytosis Activity Score (MAS) and Mastocytosis Quality of Life Questionnaire (MC-QoL) scores at 2 weeks after the final dose.
Results
In 25 patients with ISM (13 in parts A + B and 12 in part C; median age 51 years, 76% female, median 4.6 years from diagnosis), the most common treatment-related adverse events (AEs) were feeling hot (76%) and experiencing a headache (48%). No serious AEs occurred. Median MSQ and MAS symptom severity scores in part C improved (vs. baseline) across all symptoms [MSQ: skin (38–56%), gastrointestinal (49–60%), neurological (47–59%), musculoskeletal (26–27%); MAS: skin (53–59%), gastrointestinal (72–85%), neurological (20–57%), musculoskeletal (25%)]. Median MC-QoL scores improved across all domains: symptoms (39%), social life/functioning (42%), emotions (57%) and skin (44%).
Conclusions
Lirentelimab was generally well tolerated and improved symptoms and quality of life in patients with ISM. The therapeutic potential of lirentelimab should be considered for ISM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Allergology.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology IA, Berlin, Germany.
- Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria.
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany (corporate member or Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, and Berlin Institute of Health, Berlin, Germany…
- Allakos, San Carlos, CA, USA.
Förderung
- Allakos, Inc
Zitieren
APA
Siebenhaar, F., Altrichter, S., Bonnekoh, H., Hawro, T., Hawro, M., Michaelis, E. G., Kantor, A. M., Chang, A. T., Youngblood, B. A., Singh, B., Rasmussen, H. S., & Maurer, M. (2023). Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad191
Vancouver
Siebenhaar F, Altrichter S, Bonnekoh H, Hawro T, Hawro M, Michaelis EG, et al. Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad191
BibTeX
@article{Siebenhaar2023,
author = {Siebenhaar, Frank and Altrichter, Sabine and Bonnekoh, Hanna and Hawro, Tomasz and Hawro, Marlena and Michaelis, Edward G and Kantor, Andrea M and Chang, Alan T and Youngblood, Bradford A and Singh, Bhupinder and Rasmussen, Henrik S and Maurer, Marcus},
title = {Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad191}
}
EUVIMED